CRVS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
21.4M
+10.7%
19.3M
+29.7%
14.9M
+21.8%
12.2M
+15.6%
10.6M
R&D
17.8M
+11.4%
16.0M
+42.9%
11.2M
+12.4%
9.9M
+17.6%
8.5M
SG&A
3.6M
+7.4%
3.3M
-10.0%
3.7M
+62.5%
2.3M
+7.6%
2.1M
Operating Income
-21362000
-10.7%
-19297000
-29.7%
-14877000
-21.8%
-12217000
-15.6%
-10572000
EBITDA
-21267000
-10.4%
-19263000
-29.7%
-14848000
-21.8%
-12191000
-15.6%
-10544000
Net Income
-20343000
-13.3%
-17959000
-31.2%
-13692000
-11.1%
-12321000
-21.3%
-10157000
EPS (Basic)
$-0.22
-15.8%
$-0.19
-26.7%
$-0.15
+0.0%
$-0.15
-25.0%
$-0.12
EPS (Diluted)
$-0.22
-15.8%
$-0.19
-26.7%
$-0.15
+0.0%
$-0.15
-25.0%
$-0.12
Shares (Diluted)
92.5M
+0.1%
92.4M
+2.6%
90.0M
+8.2%
83.2M
+0.4%
82.8M
Corvus Pharmaceuticals (CRVS) — Financials